E A Mittendorf1, A Ardavanis2, J Symanowski3, J L Murray4, N M Shumway5, J K Litton4, D F Hale6, S A Perez2, E A Anastasopoulou2, N F Pistamaltzian2, S Ponniah7, C N Baxevanis2, E von Hofe8, M Papamichail2, G E Peoples9. 1. Department of Breast Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, USA eamitten@mdanderson.org. 2. Cancer Immunology and Immunotherapy Center, St Savas Cancer Hospital, Athens, Greece. 3. Department of Cancer Biostatistics, Levine Cancer Institute, Charlotte. 4. Department of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston. 5. Department of Hematology/Oncology, Brooke Army Medical Center, Ft Sam Houston Cancer Vaccine Development Laboratory, Department of Surgery, Uniformed Services University of the Health Sciences, Bethesda. 6. Department of Surgery, Brooke Army Medical Center, Ft Sam Houston. 7. Cancer Vaccine Development Laboratory, Department of Surgery, Uniformed Services University of the Health Sciences, Bethesda. 8. Antigen Express, Worcester. 9. Cancer Vaccine Development Program, San Antonio Department of Surgery, Uniformed Services University of the Health Sciences, Bethesda, USA.
Abstract
BACKGROUND: AE37 is the Ii-Key hybrid of the MHC class II peptide, AE36 (HER2 aa:776-790). Phase I studies showed AE37 administered with granulocyte macrophage colony-stimulating factor (GM-CSF) to be safe and highly immunogenic. A prospective, randomized, multicenter phase II adjuvant trial was conducted to evaluate the vaccine's efficacy. METHODS:Clinically disease-free node-positive and high-risk node-negative breast cancer patients with tumors expressing any degree of HER2 [immunohistochemistry (IHC) 1-3+] were enrolled. Patients were randomized to AE37 + GM-CSF versus GM-CSF alone. Toxicity was monitored. Clinical recurrences were documented and disease-free survival (DFS) analyzed. RESULTS: The trial enrolled 298 patients; 153 receivedAE37 + GM-CSF and 145 received GM-CSF alone. The groups were well matched for clinicopathologic characteristics. Toxicities have been minimal. At the time of the primary analysis, the recurrence rate in the vaccinated group was 12.4% versus 13.8% in the control group [relative risk reduction 12%, HR 0.885, 95% confidence interval (CI) 0.472-1.659, P = 0.70]. The Kaplan-Meier estimated 5-year DFS rate was 80.8% in vaccinated versus 79.5% in control patients. In planned subset analyses of patients with IHC 1+/2+ HER2-expressing tumors, 5-year DFS was 77.2% in vaccinated patients (n = 76) versus 65.7% in control patients (n = 78) (P = 0.21). In patients with triple-negative breast cancer (HER2 IHC 1+/2+ and hormone receptor negative) DFS was 77.7% in vaccinated patients (n = 25) versus 49.0% in control patients (n = 25) (P = 0.12). CONCLUSION: The overall intention-to-treat analysis demonstrates no benefit to vaccination. However, the results confirm that the vaccine is safe and suggest that vaccination may have clinical benefit in patients with low HER2-expressing tumors, specifically TNBC. Further evaluation in a randomized trial enrolling TNBC patients is warranted.
RCT Entities:
BACKGROUND: AE37 is the Ii-Key hybrid of the MHC class II peptide, AE36 (HER2 aa:776-790). Phase I studies showed AE37 administered with granulocyte macrophage colony-stimulating factor (GM-CSF) to be safe and highly immunogenic. A prospective, randomized, multicenter phase II adjuvant trial was conducted to evaluate the vaccine's efficacy. METHODS: Clinically disease-free node-positive and high-risk node-negative breast cancerpatients with tumors expressing any degree of HER2 [immunohistochemistry (IHC) 1-3+] were enrolled. Patients were randomized to AE37 + GM-CSF versus GM-CSF alone. Toxicity was monitored. Clinical recurrences were documented and disease-free survival (DFS) analyzed. RESULTS: The trial enrolled 298 patients; 153 received AE37 + GM-CSF and 145 received GM-CSF alone. The groups were well matched for clinicopathologic characteristics. Toxicities have been minimal. At the time of the primary analysis, the recurrence rate in the vaccinated group was 12.4% versus 13.8% in the control group [relative risk reduction 12%, HR 0.885, 95% confidence interval (CI) 0.472-1.659, P = 0.70]. The Kaplan-Meier estimated 5-year DFS rate was 80.8% in vaccinated versus 79.5% in control patients. In planned subset analyses of patients with IHC 1+/2+ HER2-expressing tumors, 5-year DFS was 77.2% in vaccinated patients (n = 76) versus 65.7% in control patients (n = 78) (P = 0.21). In patients with triple-negative breast cancer (HER2 IHC 1+/2+ and hormone receptor negative) DFS was 77.7% in vaccinated patients (n = 25) versus 49.0% in control patients (n = 25) (P = 0.12). CONCLUSION: The overall intention-to-treat analysis demonstrates no benefit to vaccination. However, the results confirm that the vaccine is safe and suggest that vaccination may have clinical benefit in patients with low HER2-expressing tumors, specifically TNBC. Further evaluation in a randomized trial enrolling TNBC patients is warranted.
Authors: Kevin S Clive; Josh A Tyler; G Travis Clifton; Jarrod P Holmes; Elizabeth A Mittendorf; Sathibalan Ponniah; George E Peoples Journal: Expert Rev Vaccines Date: 2010-05 Impact factor: 5.217
Authors: Edith A Perez; Edward H Romond; Vera J Suman; Jong-Hyeon Jeong; Nancy E Davidson; Charles E Geyer; Silvana Martino; Eleftherios P Mamounas; Peter A Kaufman; Norman Wolmark Journal: J Clin Oncol Date: 2011-07-18 Impact factor: 44.544
Authors: E A Mittendorf; G T Clifton; J P Holmes; E Schneble; D van Echo; S Ponniah; G E Peoples Journal: Ann Oncol Date: 2014-06-06 Impact factor: 32.976
Authors: Alan K Sears; Sonia A Perez; Guy T Clifton; Linda C Benavides; Jeremy D Gates; Kevin S Clive; Jarrod P Holmes; Nathan M Shumway; David C Van Echo; Mark G Carmichael; Sathibalan Ponniah; Constantin N Baxevanis; Elizabeth A Mittendorf; Michael Papamichail; George E Peoples Journal: Expert Opin Biol Ther Date: 2011-09-06 Impact factor: 4.388
Authors: Elizabeth A Mittendorf; Jarrod P Holmes; Sathibalan Ponniah; George E Peoples Journal: Cancer Immunol Immunother Date: 2008-06-07 Impact factor: 6.968
Authors: Michael E Gillogly; Nikoletta L Kallinteris; Minzhen Xu; Joseph V Gulfo; Robert E Humphreys; James L Murray Journal: Cancer Immunol Immunother Date: 2004-01-22 Impact factor: 6.968
Authors: George E Peoples; Jarrod P Holmes; Matthew T Hueman; Elizabeth A Mittendorf; Asna Amin; Steven Khoo; Zia A Dehqanzada; Jennifer M Gurney; Michael M Woll; Gayle B Ryan; Catherine E Storrer; Dianna Craig; Constantin G Ioannides; Sathibalan Ponniah Journal: Clin Cancer Res Date: 2008-02-01 Impact factor: 12.531
Authors: G Travis Clifton; Jennifer K Litton; Karen Arrington; Sathibalan Ponniah; Nuhad K Ibrahim; Victor Gall; Gheath Alatrash; George E Peoples; Elizabeth A Mittendorf Journal: Ann Surg Oncol Date: 2017-03-17 Impact factor: 5.344
Authors: Timothy J Vreeland; Jennifer K Litton; Na Qiao; Anne V Philips; Gheath Alatrash; Diane F Hale; Doreen O Jackson; Kaitlin M Peace; Julia M Greene; John S Berry; Guy T Clifton; George E Peoples; Elizabeth A Mittendorf Journal: Clin Immunol Date: 2018-03-21 Impact factor: 3.969
Authors: Matthew J Lin; Judit Svensson-Arvelund; Gabrielle S Lubitz; Aurélien Marabelle; Ignacio Melero; Brian D Brown; Joshua D Brody Journal: Nat Cancer Date: 2022-08-23
Authors: Olivia K Burn; Kathryn Farrand; Tara Pritchard; Sarah Draper; Ching-Wen Tang; Anna H Mooney; Alfonso J Schmidt; Sung H Yang; Geoffrey M Williams; Margaret A Brimble; Matheswaran Kandasamy; Andrew J Marshall; Kate Clarke; Gavin F Painter; Ian F Hermans; Robert Weinkove Journal: Clin Transl Immunology Date: 2022-07-03
Authors: Santiago Moragon; Cristina Hernando; Maria Teresa Martinez-Martinez; Marta Tapia; Belen Ortega-Morillo; Ana Lluch; Begoña Bermejo; Juan Miguel Cejalvo Journal: Cancers (Basel) Date: 2022-06-28 Impact factor: 6.575
Authors: Patrick M Dillon; Gina R Petroni; Mark E Smolkin; David R Brenin; Kimberly A Chianese-Bullock; Kelly T Smith; Walter C Olson; Ibrahim S Fanous; Carmel J Nail; Christiana M Brenin; Emily H Hall; Craig L Slingluff Journal: J Immunother Cancer Date: 2017-11-21 Impact factor: 13.751